Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking

• Company also announces it has now supplied 1.2 billion vaccines to Gavi, the Vaccine Alliance since 2010, helping to reach the world’s most vulnerable children.

GSK is pleased to rank second in the Access to Medicine Index (ATMI) in its ninth iteration. The Index is an independent, investor-backed report that ranks 20 of the world’s largest pharmaceutical companies on progress to improve access at scale in 113 lower income countries and focuses on 81 high burden priority diseases.  

Emma Walmsley, Chief Executive Officer, GSK said, “We are pleased to have ranked second in the latest global Access to Medicine Index (ATMI). This means we have placed first or second in the Index since its inception in 2008, and is recognition of the action we have taken, and continue to take, to ensure and accelerate access to our medicines and vaccines for people in lower income countries. As the report makes clear, partnership with governments, multilateral organisations and others is critical to making progress here. We are committed to achieving health impact at scale as a growing, successful business, positively impacting the health of 2.5 billion people by the end of the decade, including more than 1.3 billion people in lower-income countries.”

GSK’s comprehensive approach to access to medicines places the company in the top three across all categories of the ATMI report, including a first place ranking in Product Delivery which assesses how companies improve access to their products. Our dedication to improving access to transformative medicines and vaccines is a longstanding one, demonstrated through:  

• One of largest suppliers of vaccines of Gavi, with 1.2 billion vaccines now supplied to The Vaccine Alliance since 2010, helping to reach world’s most vulnerable children.  
• Around 24 million people living with HIV across 128 low- and middle-income countries are now estimated to be taking generic DTG-based treatment – representing more than 90% of people on ARVs in these countries - enabled by voluntary licencing agreements between ViiV Healthcare, Medicines Patent Pool and generic manufacturers
• Committed to investing £1 billion over next 10 years on global health R&D to get ahead of high burden infectious diseases, such as TB and Malaria, and improve access of new interventions for malaria endemic countries such as the first-ever malaria vaccine, and a new single-dose radical cure medicine.

GSK is focused on getting ahead of disease together by using our science, technology and talent to deliver health impact at scale, reducing the global health burden of infectious diseases, whilst also contributing to the long-term sustainability of GSK.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024.